Erratum to Dietary inhibitors of histone deacetylases in intestinal immunity and homeostasis [Front. Immunol. 4, (2013) 226] DOI: 10.3389/fimmu.2013.00226;Dietary inhibitors of histone deacetylases in intestinal immunity and homeostasis

Frontiers in Immunology

Volumn 4, Issue AUG, 2013, Pages

  Schilderink, R ^a   Verseijden, C ^a   de Jonge, W J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Butyrate; HDAC; Inflammatory bowel diseases; Intestinal epithelium; Short chain fatty acids

Indexed keywords

ARTICLE; ERROR;

EID: 84883717655     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00414     Document Type: Erratum

References (82)

1. Lotz M, Gütle D, Walther S, Ménard S, Bogdan C, Hornef MW. Postnatal acquisition of endotoxin tolerance in intestinal epithelial cells. J Exp Med (2006) 203:973-84. doi:10.1084/jem.20050625
2. Smythies LE, Shen R, Bimczok D, Novak L, Clements RH, Eckhoff DE, et al. Inflammation anergy in human intestinal macrophages is due to Smad-induced IkappaBalpha expression and NF-kappaB inactivation. J Biol Chem (2010) 285:19593-604. doi:10.1074/jbc.M109.069955
3. Barnard JA, Beauchamp RD, Coffey RJ, Moses HL. Regulation of intestinal epithelial cell growth by transforming growth factor type beta. Proc Natl Acad Sci U S A (1989) 86:1578-82. doi:10.1073/pnas.86.5.1578
4. Cao Y, Gao X, Zhang W, Zhang G, Nguyen AK, Liu X, et al. Dietary fiber enhances TGF-β signaling and growth inhibition in the gut. Am J Physiol Gastrointest Liver Physiol (2011) 301:G156-64. doi:10.1152/ajpgi.00362.2010
5. Li MO, Flavell RA. TGF-β: a master of all T cell trades. Cell (2008) 134:392-404. doi:10.1016/j.cell.2008.07.025
6. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limón P. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol (2010) 10:554-67. doi:10.1038/nri2808
7. Smythies LE, Sellers M, Clements RH, Mosteller-Barnum M, Meng G, Benjamin WH, et al. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest (2004) 115:66-75. doi:10.1172/JCI200519229
8. Dubos RJ, Schaedler RW. The effect of diet on the fecal bacterial flora of mice and on their resistance to infection. J Exp Med (1962) 115:1161-72. doi:10.1084/jem.115.6.1161
9. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature (2010) 464:59-65. doi:10.1038/nature08821
10. Human Microbiome Project Consortium. A framework for human microbiome research. Nature (2012) 486:215-21. doi:10.1038/nature11209
11. Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut microbiota on human health: an integrative view. Cell (2012) 148:1258-70. doi:10.1016/j.cell.2012.01.035
12. Greenblum S, Turnbaugh PJ, Borenstein E. Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. Proc Natl Acad Sci U S A (2012) 109:594-9. doi:10.1073/pnas.1116053109
13. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A (2007) 104:13780-5. doi:10.1073/pnas.0706625104
14. Treem WR, Ahsan N, Shoup M, Hyams JS. Fecal short-chain fatty acids in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr (1994) 18:159-64. doi:10.1097/00005176-199402000-00007
15. Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev (2001) 81:1031-64.
16. Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol (2006) 40:235-43. doi:10.1097/00004836-200603000-00015
17. Waldecker M, Kautenburger T, Daumann H, Busch C, Schrenk D. Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. J Nutr Biochem (2008) 19:7-7. doi:10.1016/j.jnutbio.2007.08.002
18. Kiefer J, Beyer-Sehlmeyer G, Pool-Zobel BL. Mixtures of SCFA, composed according to physiologically available concentrations in the gut lumen, modulate histone acetylation in human HT29 colon cancer cells. Br J Nutr (2007) 96(5):803-10.
19. Sanderson IR. Short chain fatty acid regulation of signaling genes expressed by the intestinal epithelium. J Nutr (2004) 134:2450S-4.
20. Nepelska M, Cultrone A, Béguet-Crespel F, Le Roux K, Doré J, Arulampalam V, et al. Butyrate produced by commensal bacteria potentiates phorbol esters induced AP-1 response in human intestinal epithelial cells. PLoS ONE (2012) 7:e52869. doi:10.1371/journal.pone.0052869
21. Hinnebusch BF, Meng S, Wu JT, Archer SY, Hodin RA. The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. J Nutr (2002) 132:1012-7.
22. Roediger WE. The colonic epithelium in ulcerative colitis: an energy-deficiency disease? Lancet (1980) 2:712-5. doi:10.1016/S0140-6736(80)91934-0
23. Siavoshian S, Segain JP, Kornprobst M, Bonnet C, Cherbut C, Galmiche JP, et al. Butyrate and trichostatin A effects on the proliferation/differentiation of human intestinal epithelial cells: induction of cyclin D3 and p21 expression. Gut (2000) 46:507-14. doi:10.1136/gut.46.4.507
24. Chen ZY, Rex S, Tseng CC. Krüppel-like factor 4 is transactivated by butyrate in colon cancer cells. J Nutr (2004) 134:792-8.
25. Mariadason JM, Barkla DH, Gibson PR. Effect of short-chain fatty acids on paracellular permeability in Caco-2 intestinal epithelium model. Am J Physiol (1997) 272:G705-12.
26. Peng L, Li ZR, Green RS, Holzman IR, Lin J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr (2009) 139:1619-25. doi:10.3945/jn.109.104638
27. Weng M, Walker WA, Sanderson IR. Butyrate regulates the expression of pathogen-triggered IL-8 in intestinal epithelia. Pediatr Res (2007) 62:542-6. doi:10.1203/PDR.0b013e318155a422
28. Kobori A, Bamba S, Imaeda H, Ban H, Tsujikawa T, Saito Y, et al. Butyrate stimulates IL-32alpha expression in human intestinal epithelial cell lines. World J Gastroenterol (2010) 16:2355-61. doi:10.3748/wjg.v16.i19.2355
29. Dalmasso G, Nguyen HT, Yan Y, Charrier-Hisamuddin L, Sitaraman SV, Merlin D. Butyrate transcriptionally enhances peptide transporter PepT1 expression and activity. PLoS ONE (2008) 3:e2476. doi:10.1371/journal.pone.0002476
30. Gaudier E, Jarry A, Blottière HM, de Coppet P, Buisine MP, Aubert JP, et al. Butyrate specifically modulates MUC gene expression in intestinal epithelial goblet cells deprived of glucose. Am J Physiol Gastrointest Liver Physiol (2004) 287:G1168-74. doi:10.1152/ajpgi.00219.2004
31. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol (2008) 9:206-18. doi:10.1038/nrm2346
32. Choudhary C, Kumar C, Gnad F, Nielsen M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science (2009) 325(5942):834-40. doi:10.1126/science.1175371
33. Allfrey VG, Faulkner R, Mirsky AE. Acetylation and methylation of histones and their possible role in regulation of RNA synthesis. Proc Natl Acad Sci U S A (1964) 51:786-94. doi:10.1073/pnas.51.5.786
34. Cheung WL, Briggs SD, Allis CD. Acetylation and chromosomal functions. Curr Opin Cell Biol (2000) 12:326-33. doi:10.1016/S0955-0674(00)00096-X
35. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature (1997) 389:349-52. doi:10.1038/38664
36. Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem (2001) 70:81-120. doi:10.1146/annurev.biochem.70.1.81
37. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene (2005) 363:15-23. doi:10.1016/j.gene.2005.09.010
38. Yuan Z, Guan Y, Chatterjee D. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science (2005) 307(5707):269-73. doi:10.1126/science.1105166
39. Sterner DE, Berger SL. Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev (2000) 64:435-59. doi:10.1128/MMBR.64.2.435-459.2000
40. Spange S, Wagner T, Heinzel T, Krämer OH. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol (2008) 41:185-98. doi:10.1016/j.biocel.2008.08.027
41. Cousens LS, Gallwitz D, Alberts BM. Different accessibilities in chromatin to histone acetylase. J Biol Chem (1979) 254:1716-23.
42. Corfe BM. Hypothesis: butyrate is not an HDAC inhibitor, but a product inhibitor of deacetylation. Mol Biosyst (2012) 8:1609-12. doi:10.1039/c2mb25028d
43. Wu S, Li RW, Li W, Li CJ. Transcriptome characterization by RNA-seq unravels the mechanisms of butyrate-induced epigenomic regulation in bovine cells. PLoS ONE (2012) 7:e36940. doi:10.1371/journal.pone.0036940
44. Belenguer A, Holtrop G, Duncan SH, Anderson SE, Calder AG, Flint HJ, et al. Rates of production and utilization of lactate by microbial communities from the human colon. FEMS Microbiol Ecol (2011) 77:107-19. doi:10.1111/j.1574-6941.2011.01086.x
45. Latham T, Mackay L, Sproul D, Karim M, Culley J, Harrison DJ, et al. Lactate, a product of glycolytic metabolism, inhibits histone deacetylase activity and promotes changes in gene expression. Nucleic Acids Res (2012) 40:4794-803. doi:10.1093/nar/gks066
46. Rajendran P, Williams DE, Ho E, Dashwood RH. Metabolism as a key to histone deacetylase inhibition. Crit Rev Biochem Mol Biol (2011) 46:181-99. doi:10.3109/10409238.2011.557713
47. Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem (2005) 96:293-304. doi:10.1002/jcb.20532
48. Thangaraju M, Cresci GA, Liu K, Ananth S, Gnanaprakasam JP, Browning DD, et al. GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res (2009) 69:2826-32. doi:10.1158/0008-5472.CAN-08-4466
49. Paroder V, Spencer SR, Paroder M, Arango D, Schwartz S Jr, Mariadason JM, et al. Na+/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: molecular characterization of SMCT. Proc Natl Acad Sci U S A (2006) 103:7270-5. doi:10.1073/pnas.0602365103
50. Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, et al. The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem (2003) 278:11312-9. doi:10.1074/jbc.M211609200
51. Le Poul E, Loison C, Struyf S, Springael JY, Lannoy V, Decobecq ME, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem (2003) 278:25481-9. doi:10.1074/jbc.M301403200
52. Ulven TT. Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets. Front Endocrinol (Lausanne) (2011) 3:111. doi:10.3389/fendo.2012.00111
53. Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature (2009) 461:1282-6. doi:10.1038/nature08530
54. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science (2013). doi:10.1126/science.1241165
55. Vinolo MA, Ferguson GJ, Kulkarni S, Damoulakis G, Anderson K, Bohlooly-Y M, et al. SCFAs induce mouse neutrophil chemotaxis through the GPR43 Receptor. PLoS ONE (2011) 6:e21205. doi:10.1371/journal.pone.0021205
56. Tazoe H, Otomo Y, Karaki S, Kato I, Fukami Y, Terasaki M, et al. Expression of short-chain fatty acid receptor GPR41 in the human colon. Biomed Res (2009) 30:149-56. doi:10.2220/biomedres.30.149
57. Karaki S, Tazoe H, Hayashi H, Kashiwabara H, Tooyama K, Suzuki Y, et al. Expression of the short-chain fatty acid receptor, GPR43, in the human colon. J Mol Histol (2007) 39:135-42. doi:10.1007/s10735-007-9145-y
58. Iwanaga T, Takebe K, Kato I, Karaki SI, Kuwahara A. Cellular expression of monocarboxylate transporters (MCT) in the digestive tract of the mouse, rat, and humans, with special reference to slc5a8. Biomed Res (2006) 27:243-54. doi:10.2220/biomedres.27.243
59. Edwards AJ, Pender SL. Histone deacetylase inhibitors and their potential role in inflammatory bowel diseases. Biochem Soc Trans (2011) 39:1092-5. doi:10.1042/BST0391092
60. Glauben R, Siegmund B. Inhibition of histone deacetylases in inflammatory bowel diseases. Mol Med (2011) 17:426-33. doi:10.2119/molmed.2011.00069
61. Glauben R, Batra A, Fedke I, Zeitz M, Lehr HA, Leoni F, et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol (2006) 176:5015-22.
62. Tao R, de Zoeten EF, Özkaynak E, Chen C, Wang L, Porrett PM, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med (2007) 13:1299-307. doi:10.1038/nm1652
63. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol (2005) 45:495-528. doi:10.1146/annurev.pharmtox.45.120403.095825
64. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov (2006) 5:769-84. doi:10.1038/nrd2133
65. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci U S A (2002) 99(5):2995-3000. doi:10.1073/pnas.052702999
66. Dinarello CA, Fossati G, Mascagni P. Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Mol Med (2011) 17(5-6):333-52. doi:10.2119/molmed.2011.00116
67. Epping MT, Wang L, Plumb JA, Lieb M, Gronemeyer H, Brown R, et al. A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2007) 104:17777-82. doi:10.1073/pnas.0702518104
68. Epping MT, Wang L, Edel MJ, Carlée L, Hernandez M, Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell (2005) 122:13-13. doi:10.1016/j.cell.2005.07.003
69. Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, Sowa Y, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem (2006) 281(19):13548-58. doi:10.1074/jbc.M510023200
70. Wilson AJ, Byun DS, Nasser S, Murray LB, Ayyanar K, Arango D, et al. HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell (2008) 19:4062-75. doi:10.1091/mbc.E08-02-0139
71. Fischle W, Dequiedt F, Hendzel MJ, Guenther MG, Lazar MA, Voelter W, et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell (2002) 9:45-57. doi:10.1016/S1097-2765(01)00429-4
72. Lahm A, Paolini C, Pallaoro M, Nardi MC, Jones P, Neddermann P, et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci U S A (2007) 104:17335-40. doi:10.1073/pnas.0706487104
73. Zoetendal EG, von Wright A, Vilpponen-Salmela T, Ben-Amor K, Akkermans AD, de Vos WM. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl Environ Microbiol (2002) 68:3401-7. doi:10.1128/AEM.68.7.3401-3407.2002
74. Quigley EM, Quera R. Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology (2006) 130:S78-90. doi:10.1053/j.gastro.2005.11.046
75. Wollowski I, Rechkemmer G, Pool-Zobel BL. Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr (2001) 73:451S-5.
76. Licciardi PV, Wong SS, Tang ML, Karagiannis TC. Epigenome targeting by probiotic metabolites. Gut Pathog (2010) 2:24. doi:10.1186/1757-4749-2-24
77. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology (2000) 119:305-9. doi:10.1053/gast.2000.9370
78. Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut (2004) 53:1617-23. doi:10.1136/gut.2003.037747
79. Sartor RB. Efficacy of probiotics for the management of inflammatory bowel disease. Gastroenterol Hepatol (N Y) (2011) 7:606-8.
80. Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol (2010) 9:88-96. doi:10.1038/nrgastro.2011.244
81. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med (2013) 368(5):407-15. doi:10.1056/NEJMoa1205037
82. Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology (2012) 143:913-6. doi:10.1053/j.gastro.2012.06.031